Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers (Q45245263)

11 December 2017

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers (English)

1 reference

11 December 2017

1 reference

1 reference

Thomas R MacGregor

1

1 reference

11 December 2017

John P Sabo

2

1 reference

11 December 2017

Stephen H Norris

3

1 reference

11 December 2017

Philip Johnson

4

1 reference

11 December 2017

Lawrence Galitz

5

1 reference

11 December 2017

Scott McCallister

6

1 reference

11 December 2017

1 November 2004

1 reference

11 December 2017

1 reference

11 December 2017

5

1 reference

11 December 2017

371-382

1 reference

11 December 2017

6

1 reference

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients

11 December 2017

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

10.1310/RRX7-49ME-27V7-MWWV

21 January 2018

Identifiers

DOI

1 reference

release_w7kfdfnugvb6vhxglv5np62lpa

11 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/w7kfdfnugvb6vhxglv5np62lpa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference